Cortexin vs IGF-1 LR3
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Cortexin
Cortexin is a polypeptide complex derived from pig brain cortex, used clinically in Russia and Eastern Europe for neurological conditions including stroke recovery, traumatic brain injury, and cognitive decline.
Full details →IGF-1 LR3
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.
Full details →Side-by-Side Comparison
| Aspect | Cortexin | IGF-1 LR3 |
|---|---|---|
| Mechanism | Contains a mixture of neuropeptides and amino acids that support neuronal metabolism, provide neuroprotection, and enhance synaptic transmission. Specific mechanisms not fully characterized. | Binds to IGF-1 receptors to promote protein synthesis, muscle growth, and fat metabolism. The LR3 modification (13 amino acid extension and arginine substitution) extends half-life from minutes to 20-30 hours. |
| Typical Dosage | Clinical protocols: 10mg intramuscularly once daily for 10-20 days. May be repeated after 3-6 month interval. | Research protocols typically use 20-100mcg daily, often divided into multiple injections or administered bilaterally to target muscles. |
| Administration | Intramuscular injection. Comes as lyophilized powder requiring reconstitution. Treatment given in courses rather than continuously. | Intramuscular injection (site-specific growth) or subcutaneous for systemic effects. Often cycled 4-6 weeks on, equal time off. |
| Side Effects | Generally well-tolerated. May cause injection site reactions or mild allergic responses in sensitive individuals. | Hypoglycemia, joint pain, water retention, potential jaw/hand growth with extended use, and injection site reactions. |
| Best For |
What They Have in Common
Both Cortexin and IGF-1 LR3 are commonly used for: